|
1. Jain, R., & Choe, S. (2010). Clinical pharmacology and biopharmaceutics review: NDA 22-505 (EGRIFTA/Tesamorelin Acetate). U.S. Food and Drug Administration, Center for Drug Evaluation and Research. NDA 22-505.
2. Fourman, L. T., Czerwonka, N., Feldpausch, M. N., Weiss, J., Mamputu, J. C., Falutz, J., Morin, J., Marsolais, C., Stanley, T. L., & Grinspoon, S. K. (2017). Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV. AIDS (London, England), 31(16), 2253–2259. doi:10.1097/QAD.0000000000001614
3. Falutz, J., Allas, S., Blot, K., Potvin, D., Kotler, D., Somero, M., Berger, D., Brown, S., Richmond, G., Fessel, J., Turner, R., & Grinspoon, S. (2007). Metabolic effects of a growth hormone–releasing factor in patients with HIV. New England Journal of Medicine, 357(23), 2359–2370. doi:10.1056/NEJMoa072375
|